Other voices have been telling the story of compounding—at FDA, in the halls of Congress, and in the media. To hear them tell it, you work in a dangerous, unregulated profession that puts patients at risk.
A big thank you and warm welcome to APC’s 2023 Corporate Patrons.
In a meeting last week with APC and NCPA reps, FDA Center for Veterinary Medicine’s Dr. Bill Flynn indicated that the agency’s stated April 1 date for commencing GFI 256 enforcement was not ironclad.
Check out the latest public policy update video from APC Director of Public Policy Savannah Cunningham, PharmD.
Late Thursday we learned that FDA has updated its January 20 GFI on ibuprofen compounding by 503Bs. The update would allow 503Bs to sell the ibuprofen suspension they prepare to 503A pharmacies.
Compounding the Joy is the third year of our 3-year media campaign to protect compounding. We initially focused on hormones (and that fight continues) but we are expanding our mandate to secure the future of all compounding.
EduCon is your key to being an effective team member in a well-run compounding operation. Don't miss it!
The Covid-19 national and public health emergencies are ending May 11, which means temporary guidance for industry that allowed 503As and 503Bs to prepare 13 COVID drugs for hospitals during the PHE will expire as well.
It's time to get a clue about the value of planning now— while you’re young (at heart?)—to assure you have the funds you need to live well into your, um, maturity.
In November 2022, APC submitted comments to Maine Board of Pharmacy on its proposed rule in Chapter 42 regarding compounding drugs for veterinary office use.
FOLLOW US
